Literature DB >> 15365991

Sequence variations of the alpha-globin genes: scanning of high CG content genes with DHPLC and DG-DGGE.

Giuseppina Lacerra1, Mirella Fiorito, Gennaro Musollino, Francesca Di Noce, Maria Esposito, Vincenzo Nigro, Carlo Gaudiano, Clementina Carestia.   

Abstract

The alpha-globin chains are encoded by two duplicated genes (HBA2 and HBA1, 5'-3') showing overall sequence homology >96% and average CG content >60%. alpha-Thalassemia, the most prevalent worldwide autosomal recessive disorder, is a hereditary anemia caused by sequence variations of these genes in about 25% of carriers. We evaluated the overall sensitivity and suitability of DHPLC and DG-DGGE in scanning both the alpha-globin genes by carrying out a retrospective analysis of 19 variant alleles in 29 genotypes. The HBA2 alleles c.1A>G, c.79G>A, and c.281T>G, and the HBA1 allele c.475C>A were new. Three pathogenic sequence variations were associated in cis with nonpathogenic variations in all families studied; they were the HBA2 variation c.2T>C associated with c.-24C>G, and the HBA2 variations c.391G>C and c.427T>C, both associated with c.565G>A. We set up original experimental conditions for DHPLC and DG-DGGE and analyzed 10 normal subjects, 46 heterozygotes, seven homozygotes, seven compound heterozygotes, and six compound heterozygotes for a hybrid gene. Both the methodologies gave reproducible results and no false-positive was detected. DHPLC showed 100% sensitivity and DG-DGGE nearly 90%. About 100% of the sequence from the cap site to the polyA addition site could be scanned by DHPLC, about 87% by DG-DGGE. It is noteworthy that the three most common pathogenic sequence variations (HBA2 alleles c.2T>C, c.95+2_95+6del, and c.523A>G) were unambiguously detected by both the methodologies. Genotype diagnosis must be confirmed with PCR sequencing of single amplicons or with an allele-specific method. This study can be helpful for scanning genes with high CG content and offers a model suitable for duplicated genes with high homology. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15365991     DOI: 10.1002/humu.20088

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  4 in total

1.  Molecular Determination of Vascular Endothelial Growth Factor, miRNA-423 Gene Abnormalities by Utilizing ARMS-PCR and Their Association with Fetal Hemoglobin Expression in the Patients with Sickle Cell Disease.

Authors:  Abdullah Hamadi; Rashid Mir; Ali Mahzari; Abdulrahim Hakami; Reema Almotairi; Gasim Dobie; Fawaz Hamdi; Mohammed Hassan Nahari; Razan Alhefzi; Mohammed Alasseiri; Nora Y Hakami; Hadeel Al Sadoun; Osama M Al-Amer; Jameel Barnawi; Hassan A Madkhali
Journal:  Curr Issues Mol Biol       Date:  2022-06-01       Impact factor: 2.976

2.  Extensive scanning of the calpain-3 gene broadens the spectrum of LGMD2A phenotypes.

Authors:  G Piluso; L Politano; S Aurino; M Fanin; E Ricci; V M Ventriglia; A Belsito; A Totaro; V Saccone; H Topaloglu; A C Nascimbeni; L Fulizio; A Broccolini; N Canki-Klain; L I Comi; G Nigro; C Angelini; V Nigro
Journal:  J Med Genet       Date:  2005-09       Impact factor: 6.318

3.  α-Thalassemia associated with hb instability: a tale of two features. the case of Hb Rogliano or α1 Cod 108(G15)Thr→Asn and Hb Policoro or α2 Cod 124(H7)Ser→Pro.

Authors:  Maria Grazia Bisconte; Mercedes Caldora; Gennaro Musollino; Giovanna Cardiero; Angela Flagiello; Gaetana La Porta; Laura Lagona; Romeo Prezioso; Gabriele Qualtieri; Carlo Gaudiano; Emilia Medulla; Antonello Merlino; Piero Pucci; Giuseppina Lacerra
Journal:  PLoS One       Date:  2015-03-02       Impact factor: 3.240

4.  Effect of Mutations on mRNA and Globin Stability: The Cases of Hb Bernalda/Groene Hart and Hb Southern Italy.

Authors:  Giovanna Cardiero; Gennaro Musollino; Maria Grazia Friscia; Rosario Testa; Lucrezia Virruso; Caterina Di Girgenti; Mercedes Caldora; Rosario Colella Bisogno; Carlo Gaudiano; Giuseppe Manco; Giuseppina Lacerra
Journal:  Genes (Basel)       Date:  2020-07-31       Impact factor: 4.096

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.